Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Accumulated Expenses (2016 - 2025)

ImmunityBio (IBRX) has disclosed Accumulated Expenses for 12 consecutive years, with $46.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 15.42% to $46.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $46.8 million, a 15.42% increase, with the full-year FY2025 number at $46.8 million, up 15.42% from a year prior.
  • Accumulated Expenses was $46.8 million for Q4 2025 at ImmunityBio, up from $43.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $64.9 million in Q3 2023 to a low of $27.9 million in Q1 2025.
  • A 5-year average of $45.7 million and a median of $43.6 million in 2024 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 23387.2% in 2021, then crashed 43.3% in 2024.
  • ImmunityBio's Accumulated Expenses stood at $51.4 million in 2021, then decreased by 18.61% to $41.8 million in 2022, then rose by 2.11% to $42.7 million in 2023, then decreased by 4.98% to $40.6 million in 2024, then increased by 15.42% to $46.8 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Accumulated Expenses are $46.8 million (Q4 2025), $43.6 million (Q3 2025), and $35.7 million (Q2 2025).